Investigational Apitegromab
Investigational apitegromab, a selective myostatin activation inhibitor, effectively preserved lean mass when combined with tirzepatide (Zepbound) in a randomized phase II trial, suggesting it could help fight “Ozempic butt.” (Nature Medicine, BBC News)
Retatrutide Prescriptions
The FDA hasn’t yet reviewed retatrutide for safety and effectiveness, but doctors are prescribing the investigational weight-loss drug anyhow. (CBS News)
Mazdutide Effectiveness
Chinese adults with obesity lost 15.15% more weight with the dual GLP-1/glucagon agonist mazdutide compared with placebo in the GLORY-2 randomized trial presented at the American Diabetes Association (ADA) annual meeting. (JAMA)
Medicare Insulin Cap
An interrupted time series analysis published in JAMA found that Medicare’s $35 insulin cap decreased and stabilized out-of-pocket costs, increasing use among people with previously high costs. Catch up on more research from the ADA meeting here.
Insulin Injection During Match
Tennis player Alexander Zverev gave himself an insulin injection for his type 1 diabetes during his French Open final win on Sunday. (Daily Express U.S. via AOL)
Government Regulations on Food
In a special edition of the American Journal of Public Health, leading nutrition experts called for sweeping government regulations on ultraprocessed foods. (STAT)
Protein Source and Weight Change
Swapping animal protein for plant protein was associated with a decrease in body weight among postmenopausal women, independent of changes in energy intake, a secondary analysis of a randomized trial showed. (Menopause)
Gender Affirming Care Investigation
Amid a federal investigation, the Cleveland Clinic reached an agreement to provide detransition care and not perform gender-affirming procedures for minors, the Justice Department announced.
GLP-1 Drug Efficacy
HRS-7535, an oral nonpeptide GLP-1 drug, improved glycemic control and was linked to modest weight reductions in a Chinese randomized trial of adults with type 2 diabetes inadequately controlled with metformin. (JAMA Network Open)
Behavioral Interventions
In a qualitative study, patients described GLP-1 drug therapy functioning as a facilitator rather than a replacement for lifestyle change, emphasizing the need for behavioral interventions alongside pharmacotherapy to sustain treatment benefits. (JAMA Network Open)
Semaglutide and Aging
Use of semaglutide (Ozempic, Wegovy) appeared to slow epigenetic aging in a randomized trial of people with HIV-associated lipohypertrophy. (Nature Communications)
Insurance Coverage Changes
Health insurer Cigna dropped coverage of GLP-1 weight-loss drugs for its own employees. (Reuters)
Disclaimer: This content is for informational purposes only and should not be considered as medical advice. Always consult a healthcare professional for medical concerns.
Fuente: https://www.medpagetoday.com/endocrinology/generalendocrinology/121675
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
